Allegra (Fexofenadine) Dosing and Safety Guidelines
Dosing Recommendations
For adults and children ≥12 years: fexofenadine 60 mg twice daily or 120-180 mg once daily is the standard dose for allergic rhinitis 1. The FDA-approved dosing is:
- 12 Hour formulation: 60 mg every 12 hours (maximum 2 tablets/24 hours) 1
- 24 Hour formulation: 180 mg once daily (maximum 1 tablet/24 hours) 1
For children 6-11 years: fexofenadine 30 mg twice daily is the recommended dose 2. This has been extensively studied with over 10,000 patient-days of exposure demonstrating excellent safety and efficacy in reducing all seasonal allergic rhinitis symptoms including nasal congestion 2.
For children 2-5 years: fexofenadine 30 mg twice daily has been shown safe and well-tolerated 3. The capsule contents can be mixed with approximately 10 mL of applesauce to facilitate administration 3.
For children under 2 years: do not use 1. This aligns with FDA guidance on OTC antihistamines in very young children.
Special Populations
Key Safety Profile
Fexofenadine is truly non-sedating at all doses, including those exceeding FDA-approved recommendations 4. This distinguishes it from other second-generation antihistamines:
- No sedation: Fexofenadine, loratadine, and desloratadine do not cause sedation at recommended doses 4
- No performance impairment: Even at doses up to 240 mg/day (double the maximum recommended dose), fexofenadine shows no cognitive or psychomotor impairment 5, 6, 7
- No brain penetration: PET studies confirm zero H1-receptor occupancy in the brain, explaining the complete absence of CNS effects 7
This contrasts with cetirizine (13.7% drowsiness vs 6.3% placebo) and intranasal azelastine (11.5% somnolence), which may cause sedation at recommended doses 4.
Contraindications and Drug Interactions
No clinically significant drug interactions have been identified with fexofenadine 5. Specifically:
- No cardiac effects when combined with erythromycin or ketoconazole 6
- No QT prolongation or cardiotoxicity 5, 6
- Does not inhibit cardiac K+ channels 6
This excellent interaction profile makes fexofenadine particularly safe in patients on multiple medications.
Pediatric Safety Considerations
Second-generation antihistamines like fexofenadine have demonstrated a very good safety profile in young children, unlike first-generation antihistamines and OTC cough/cold medications 4. Between 1969-2006, there were 69 fatalities associated with first-generation antihistamines in children ≤6 years, primarily from overdose and toxicity 4. In contrast:
- Treatment-emergent adverse events with fexofenadine in children 2-5 years were similar to placebo (9.5% vs 8.2%) 3
- Most common adverse event was headache (5.8% with fexofenadine 30 mg vs 4.3% placebo in children 6-11 years) 2
- No sedative effects observed in any pediatric age group 2, 3
Pregnancy Considerations
While fexofenadine has no reports of increased congenital malformations and negative animal studies for teratogenicity, no epidemiologic studies in human pregnancy have been published 4. The accumulated safety data on second-generation antihistamines during pregnancy are comparable to first-generation agents, but first-generation antihistamines have longer track records despite their less favorable side effect profiles 4.
Clinical Efficacy Context
Fexofenadine is as effective as loratadine and cetirizine for seasonal allergic rhinitis 6. It provides:
- Rapid onset of relief (≤2 hours) 6
- Effective reduction of sneezing, rhinorrhea, itchy nose/palate/throat, and ocular symptoms 6
- Small improvements in nasal congestion (may require addition of pseudoephedrine for severe congestion) 6
- Greater quality of life improvements than loratadine, to a clinically meaningful extent 6
However, intranasal corticosteroids remain the most effective medication class for allergic rhinitis overall 4, and should be considered first-line for moderate-to-severe symptoms.